about
A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.Loss of IkappaB alpha-mediated control over nuclear import and DNA binding enables oncogenic activation of c-RelMapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblastsMouse mammary tumor virus c-rel transgenic mice develop mammary tumors.The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cellsRepression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformationCAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stressThe v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation.A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms.
P2860
Q24537405-E101D5D0-CD87-4833-A5FE-8021B5D99863Q33778864-D15F693A-F6B5-4E86-A122-6E634DF57EF1Q33957101-5D7EC9A3-385D-43D8-A28D-4847F5DCBD87Q34012219-1D694182-5B18-4FA7-8461-0B81F0E90048Q35169909-B8FB1FB7-0163-401C-BE99-C8B15EE9D75AQ35829918-3B5BCB6D-C302-4701-BEAD-F399417E7052Q35839572-FBBA330F-46B2-4E4F-B97D-37F9C10065E9Q36495569-D9849E9C-3A7B-4A56-A014-91249E446410Q36630907-2EAD3687-EEDA-47F7-99D2-2CA8FADBD47FQ36949574-C47D916B-A931-4F4D-AC21-56D812439974Q38354859-C53A2223-3F5D-4768-8017-17D9DB6F09FDQ38355384-3287AB18-16D0-428F-B996-8C2BB0E0A67DQ39294110-58A720F3-2A18-4F9C-B936-2BB59DFA71C0Q39608218-C88A8252-92ED-425A-BB3A-66803FFEED84Q39874406-06019C91-6548-4C85-8032-559AAB0874D9
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
In vivo evolution of c-rel oncogenic potential.
@ast
In vivo evolution of c-rel oncogenic potential.
@en
type
label
In vivo evolution of c-rel oncogenic potential.
@ast
In vivo evolution of c-rel oncogenic potential.
@en
prefLabel
In vivo evolution of c-rel oncogenic potential.
@ast
In vivo evolution of c-rel oncogenic potential.
@en
P2093
P2860
P1433
P1476
In vivo evolution of c-rel oncogenic potential.
@en
P2093
E H Humphries
R Hrdlicková
P2860
P304
P407
P577
1994-04-01T00:00:00Z